Poxel’s Imeglimin Boosts Glucose-Sensing in Trial
LONDON – Poxel SA generated new patient data on its diabetes treatment Imeglimin, demonstrating it has a novel mechanism of action and showing the drug could be used in combination with existing orally administered Type II diabetes treatments.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter